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Abstract
Background: Increasingly, it is argued that clinical trials struggle to recruit participants because they do not
respond to key questions or study treatments that patients will be willing or able to use. This study explores how
elicitation of patient-preferences can help designers of randomized controlled trials (RCTs) understand the impact of
changing modifiable aspects of treatments or trial design on recruitment.
Methods: Focus groups and a discrete choice experiment (DCE) survey were used to elicit preferences of people with
scleroderma for autologous hematopoietic stem cell transplant (AHSCT) treatment interventions. Preferences for seven
attributes of treatment (effectiveness, immediate and long-term risk, care team composition and experience, cost, travel
distance) were estimated using a mixed-logit model and used to predict participation in RCTs.
Results: Two hundred seventy-eight people with scleroderma answered the survey. All AHSCT treatment attributes
significantly influenced preferences. Treatment effectiveness and risk of late complications contributed the most to
participants’ choices, but modifiable factors of distance to treatment center and cost also affected preferences.
Predicted recruitment rates calibrated with participation in a recent trial (33%) and suggest offering a treatment closer
to home, at lower patient cost, and with holistic, multidisciplinary care could increase participation to 51%.
Conclusions: Through a patient engaged approach to preference elicitation for different features of AHSCT treatment
options, we were able to predict what drives the decisions of people with scleroderma to participate in RCTs.
Knowledge regarding concerns and the trade-offs people are willing to make can inform clinical study design,
improving recruitment rates and potential uptake of the treatment of interest.
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Introduction
There is a long, established recognition that clinical re-
search does not always translate to improvements in pa-
tient care and outcomes [1–3]. Randomized clinical
trials are considered to be one of the most rigorous
sources of evidence to evaluate treatments and services
and should have the greatest potential to impact posi-
tively on the health care we provide to patients. How-
ever, it is argued that the majority of clinical trials are
not useful since they do not respond to key questions
[4], often fail to inform clinical decision-making [2], fre-
quently fail to meet their recruitment targets [5], and
contribute to an estimated 85% of wasted research
spending [3, 4]. The proposed solutions to reducing
waste and increasing value consistently include a greater
role of patient preferences and priorities in the research
process [1–5].
There has been a push to enhance involvement of pa-
tients in the research process, for example the National
Institute for Health Research (NIHR) in the UK, Patient-
Centered Outcomes Research Institute (PCORI) in the
US, and Strategy for Patient Oriented Research (SPOR)
in Canada [6–8]. Each requires active patient and public
involvement (PPI) in the research they fund and pro-
motes multiple methods to support inclusion of patients
[9]. The role of and evaluation of impact of PPI in trials
appears to focus on the process of enrolling and retain-
ing potential participants; a recent review of the impact
of PPI identified 26 clinical trials that used PPI to design
strategies for recruitment and retention, patient informa-
tion, and ways to identify and approach potential partici-
pants [10]. Organizations like the James Lind Alliance
are improving understanding of patient research prior-
ities in specific conditions or areas of health care [11],
and pragmatic trials designs which reflect the real world
are emerging [12, 13]. There has, however, been less at-
tention on the role of PPI in co-production of research,
which involves sharing power with patients from the
point of generating the specific questions that the trial
should answer or the design of the trial [14], and there is
a lacuna of published methods to understand the extent
to which trials of specific treatments and research ques-
tions are patient-centered and feasible in a target popu-
lation. PPI in the design of trials has been consistently
recommended, with specific reference to waste and inef-
ficiency occurring due to choice of treatment and design
of trials [15], and recognition that useful research should
be patient-centered and “aligned with patient priorities,
the utilities patients assign to different problems and
outcomes, and how acceptable they find interventions”
[2]. A recent paper proposed a role for using discrete
choice experiments (DCE), a quantitative technique to
elicit user preferences, in the design of complex inter-
ventions to promote higher uptake and adherence [16].
This type of approach could be used routinely at a for-
mative stage of trial design to ensure that procedures,
interventions, and outcomes are those that align with
patient preferences and improves the likelihood of im-
pact from research.
This paper describes a systematic approach to under-
stand patients’ preferences to inform the design of a fu-
ture clinical trial. It focuses on modifiable factors of the
study or treatment (e.g., logistics, quality of care, and in-
formation provided), rather than non-modifiable factors
(e.g., attitude to risk about an experimental treatment)
[17]. Just as successful companies offer products and
services that consumers want and need, a successful and
useful trial should be investigating treatments and ser-
vices that patients value and would be willing to use. By
working with, listening to, and understanding patient
preferences, we believe these methods could inform the
design of treatments and services studied in RCTs, out-
come measures, and the effect sizes needed and ultim-
ately increase participation and retention rates of RCTs.
Methods
Case study
The “Scleroderma: Cyclophosphamide or Transplantation
(SCOT)” trial, which tested autologous hematopoietic
stem cell transplant (AHSCT) for people with sclero-
derma, is an example of a published trial which experi-
enced difficulty in recruiting participants. The trial
initially planned to recruit 226 participants to study event-
free survival over 54months [18]. However, slow recruit-
ment led to a downward revision of the recruitment target
to 114 participants, broadening of the entry criteria, and a
change in the primary outcome measure to the global
rank composite score, a hierarchy of 5 outcomes ranging
from death to skin involvement [18]. Despite these
changes, only 75 people were randomized (33%) due to
“slow accrual” [18], which was later attributed to concerns
about transportation and insurance coverage among po-
tential participants, the latter being an important barrier
to trial participation in the United States (US) [19].
Approach
We conducted an online DCE survey to elicit the prefer-
ences of people with scleroderma for AHSCT treatment.
DCEs were originally developed as a market research
method to establish the value of goods and services, and
in turn pricing, ahead of market launch, and have now
been used in health economics for over 20 years. Prefer-
ences for new treatments and services are a natural ap-
plication of this methodology because they are not yet
available in routine patient care, and there is uncertainty
about whether patients will be willing to use them. As
such, quantitative methods to elicit patient preferences,
such as DCEs, are recommended by the US Food and
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Drug Administration (FDA) as supplementary evidence
to support decision makers achieving more patient-
oriented decisions regarding trade-offs between benefits
and risks [20].
Patient and public involvement
A conversation between patients, clinicians, and re-
searchers (TB, MHu, MH, NB) about the interpretation of
the SCOT trial for patient-physician decision-making re-
sulted in development of a patient-oriented project, to ex-
plore how patient perspectives could be formally elicited
and used in design of RCTs. Two patient partners (TB, JB)
were integrated into the research team and contributed to
all stages of the project, including formulation of the
research question and funding application (TB), survey
design, recruitment, data analysis, interpretation, and dis-
semination (TB and JB); this process and the level of en-
gagement aligns with the concept of co-production in PPI
[14] which has been described elsewhere and our frame-
work for patient involvement is summarized in the sup-
plementary material (Table S1) [21, 22].
DCE survey design
The survey consisted of four main sections: demographic
information, information about AHSCT treatment (gen-
eral information about eligibility and treatment includ-
ing the potential process, risks and benefits), the DCE
component, and questions about their health.
The methods to develop the DCE followed published
international guidelines for conducting DCEs in health
[23–25] Participants were asked to choose between
“AHSCT treatment A,” “AHSCT treatment B,” and a
fixed “no AHSCT treatment” alternative. An example
choice set is shown in Fig. 1. Treatment characteristics
(attributes) were developed using qualitative methods
[22], as recommended by best practice [24], and reflect
the most important aspects of the decision about
whether or not to undergo AHSCT treatment (Supple-
mentary material (Table S1)). We used a nominal group
technique (NGT) in a focus group with eight people
with scleroderma in British Columbia, as part of a
patient-oriented qualitative approach to design the DCE
[22]. The NGT was designed to allow in-person and vir-
tual participation to allow the perspectives of sclero-
derma patients in urban, rural and remote settings to
participate. Participants were recruited via an email ad-
vert sent to all members of the Scleroderma Associations
of British Columbia. The NGT approach had the advan-
tage that it began with all potential attributes being gen-
erated by the patients participating in the group and
finished with agreement on the most important features
to be included as attributes. The NGT process was
chaired by a qualitative researcher with experience in fa-
cilitating focus groups (SM) and a patient partner with
lived experience of scleroderma on our research team
(TB) and was completed within 2 h. The NGT process
has been documented in detail elsewhere (Munro S,
Aguiar M, Burch T, Kaal K, Trenaman L, Hudson M,
et al. What are the factors that patients prioritise when
considering novel treatments? A case study of systemic
sclerosis using the nominal group technique. Submitted).
Briefly, during the NGT process, participants considered
what factors would matter to them if considering stem
cell transplant for their scleroderma; each participant
generated ideas independently, before all ideas were
shared, recorded, and discussed. Once all ideas had been
recorded and discussed, each participant independently
voted on the five most important factors to them, and
then shared these rankings to the rest of the group. Fi-
nally, the results were then discussed as a group.
The levels of each of the attributes were developed
based on the literature, and the expert opinion of people
with scleroderma (TB, JB) and clinicians (MHu) in the
team, and qualitative data collected for this study. The
final list of attributes and levels is presented in Table 1.
The combination of all levels in the DCE would result
in a total of 9216 possible unique choice sets. We used
Ngene software to create an experimental design opti-
mized to combine the levels in as few choice sets as pos-
sible, selecting the choice sets that yield more
information about participants’ choices [30]. This re-
sulted in 24 different choice sets, which were divided
into 4 blocks of 6. Each participant was randomized to
one of 6 survey versions which contained two blocks of
questions and therefore made 12 choices.
We pilot-tested the survey in think-aloud interviews
with seven people with scleroderma to assess their inter-
pretation of the questions and ability to complete the
task. This piloting process led to minor changes to the
survey, for example reducing the length and the com-
plexity of instructions for clarity, providing an estimate
of the time required to complete the survey (as well as
emphasizing that respondents could leave and return to
the survey), and adding a progress bar.
The survey was translated into French, using an ap-
proved translation service of the Scleroderma Patient-
centered Intervention Network (SPIN) cohort, who rou-
tinely develop condition-specific surveys in French. Eng-
lish and French versions of the survey were distributed
to the mailing lists of the SPIN patient cohort [31] and
the Scleroderma Associations of British Columbia and
Quebec in Canada in late 2019. Ethical approval was
granted by the University of British Columbia behav-
ioural ethics board (H18-02389).
Statistical analysis
The DCE data was analyzed in STATA 15.6 software
using a mixed multinomial logit (random parameters
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Fig. 1 Example choice set presented to participants
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logit) model [32]. The MXL model accounts for prefer-
ence heterogeneity in the population preferences by
allowing selected parameter estimates (coefficients) to
vary as random parameters rather than treating coeffi-
cients as fixed parameters. This infers that each partici-
pant in the sample has an individual-specific preference
which leads to a specific parameter estimate on the dis-
tribution for each coefficient. Attribute levels were ef-
fects coded which enables the model to display
coefficients for each single level per attribute. Effects
coded coefficients are interpreted as relative preferences
(with a central utility of 0) which are meaningless unless
they are interpreted relative to the coefficients for the
other attributes [33].
Predictions of recruitment to an RCT were calculated
by first estimating the indirect utility of a specific AHSC
T treatment option and no treatment, calculated as the
sum of the coefficients for the levels of each attribute
which best describes each scenario. The probability of
participation in the trial was then calculated by dividing
the exponential of the indirect utility of the AHSCT
treatment by the sum of the exponential indirect utilities
of AHSCT treatment and no treatment.
Understanding preferences
The model provides parameter estimates of the mean ef-
fect (coefficient) of each attribute level and the standard
deviation of this parameter estimate for the population.
Table 1 Final list of attributes, levels, and data sources
Attribute Levels Sources/references
Years after treatment without further scleroderma
organ damage
1. 1 year (opt-out level) Expert opinion (clinician);




Immune suppression treatment and risk of
immediate complications
1. No additional risk of immediate complications (opt-out level) Carreras et al. [26]
2. Chemotherapy; risk of complications which could lead to death:
10% (10 in 100)
3. Low dose chemotherapy and full body irradiation; risk of
complications which could lead to death: 5% (5 in 100)
4. Low dose chemotherapy and targeted irradiation; risk of
complications which could lead to death: 2.5% (2.5 in 100)
Late complications (i.e., cancer) 1. No additional risk of late complications (opt-out level) Refs [26–29]
2. Risk of late complication from treatment (e.g., cancer) in the
future: 5% (5 in 100)
3. Risk of late complication from treatment (e.g., cancer) in the
future: 10% (10 in 100)
4. Risk of late complication from treatment (e.g., cancer) in the
future: 20% (20 in 100)
Team care (in addition to the standard medical care) 1. No additional team members (opt-out level) Qualitative work
2. Extended medical team: rheumatologist, hematologist,
cardiologist, respirologist, nurse
3. Multidisciplinary care: extended medical team + allied health
professionals to provide mental, wellbeing and nutritional support
Number of people with scleroderma the
hematologist has treated using AHSC treatment
1. No information (opt-out level) Qualitative work/expert
opinion (patient/clinician)
2. Less than 5 patients
3. 5 or more patients
Additional cost to you (expenses not covered by the
provincial health plan, nor your health insurance)





Additional distance of treatment center to your
home
1. 0 km (opt-out level) Qualitative work/expert
opinion (patient)
2. Between 50 and 300 km
3. Between 300 and 1000 km
4. More than 1000 km
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The resulting coefficients indicate the relative importance
of the levels of an attribute and the face validity of the re-
sults. The bigger the coefficient, the greater the import-
ance of the attribute level for the decision. Positive
coefficient indicates that respondents attach a positive
value to that particular level, while a negative coefficient
indicates indicate a negative value to that level. Higher
risks of adverse events, for example, are expected to have
negative coefficients.
Using preferences to predict participation in a trial
The inclusion of the fixed “no AHSCT treatment” opt-out
alternative allows uptake to be predicted [34]. The coeffi-
cients for each attribute level can be used to estimate the
utility (or value) of a treatment, based on the levels of each
attribute which best describe that treatment. As a test of
the external validity of our results, we predicted the up-
take for the SCOT trial, based on estimates of preferences
for treatment from the DCE results (stated preferences),
and compared this with the observed 33% (75/226) par-
ticipation rate of the SCOT trial (revealed preference).
Levels for the SCOT trial were chosen in consultation
with people with scleroderma and clinicians in our team
and the trial publication (Table 2) [18].
We then predicted the potential impact on participa-
tion in a trial which offered a treatment whose modifi-
able attributes (cost, distance, team care) were adapted
to be more aligned with preferences of people with
scleroderma (made more favorable by one level).
Results
Sample
Two hundred seventy-eight people with scleroderma
(71%) completed the survey (out of 389 who started the
survey) (Table 3). The majority of the sample identified
as women (88%), were aged 40 years or older (90%),
Caucasian (74%), and lived in Canada (45%), the USA
(28%), or France (17%). Over half of the sample (54%)
had diffuse scleroderma, the main diagnosis for which
AHSCT treatment is currently indicated, 44% had lim-
ited scleroderma, and the remaining 3% reported other
types of scleroderma. Disease duration ranged from 0 to
54 years (mean 13.9 year, SD 9.9 years) and 51% of the
respondents reported being 40–59 years old at diagnosis.
Disease duration was longer for those with limited
scleroderma (16.0 years, standard deviation 11.4 years)
than those with diffuse scleroderma (12.3 years, standard
deviation 8.3 years) (p = 0.002). Of those with diffuse
scleroderma, 19 (13%) people had disease duration of
less than 5 years, which is broadly representative of the
potential candidates for AHSCT treatment.
Preferences of people with scleroderma
Face validity
Figure 2 shows that estimated preferences for attribute levels
were ordered as expected, supporting the face validity of the
survey. For example, larger benefits (e.g., 5 or 10 years with-
out further organ damage) from treatment contributed posi-
tively to preferences, while small benefits (e.g., 1 or 2 years
without further organ damage) contributed negatively. Simi-
larly, lower levels of risks, costs, and travel distance contrib-
uted positively to preferences, while higher levels of these
characteristics contributed negatively
Preferences for aspects of AHSCT
The most important characteristics of a decision to
undergo AHSCT, or not, were the potential risks and
benefits; the highest levels of the risk of either the imme-
diate or late complications would either completely (late
complications) or partially (immediate complications)
offset preferences for the highest level of benefit (10
years without further organ damage). The cost of
Table 2 Description of the AHSCT treatment interventions
Original trial design Patient-oriented trial design
Years after treatment without
further scleroderma organ
damage
1–10 years 1–10 years
Members of the care team Extended medical team: rheumatologist,
hematologist, cardiologist, respirologist, nurse
Multidisciplinary care: extended medical team + allied health
professionals to provide mental, wellbeing and nutritional
support
Immediate complication Low dose chemotherapy and full body irradiation;
risk of complications which could lead to death: 5%
(5 in 100)
Low dose chemotherapy and full body irradiation; risk of
complications which could lead to death: 5% (5 in 100)
Late complications Risk of late complication from treatment (e.g., cancer)
in the future: 20% (20 in 100)
Risk of late complication from treatment (e.g., cancer) in the
future: 20% (20 in 100)
Hematologist’s experience 5 or more patients 5 or more patients
Additional cost to you $1000–$5000 $0 to $1000
Distance of the treatment
center from your home
More than 1000 km Between 50 and 300 km
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treatment to an individual was a priority for people with
scleroderma; the magnitude of importance of cost to in-
dividuals was only slightly smaller than the risk of imme-
diate complications from treatment. Distance was not
statistically significant until it exceeded 1000 km. The
experience of the transplant hematologist in treating
people with scleroderma was a priority only at very low
(negative preference) or high levels (positive preference).
There was a preference for additional members of the
care team, but this was only small and statistically sig-
nificant for an extended medical team.
Predicting trial participation based on preferences for
aspects of AHSCT
External validity
Using preferences for attribute levels from our model, at
an expected benefit of 5 years without further organ
damage, which most closely matches the intended SCOT
trial primary outcome, we predict that around 1 in 3
people (34%) with scleroderma would be willing to
participate in a trial of this treatment (shown in blue,
Fig. 3). This corresponds very closely with the reported
participation in the SCOT trial, which recruited 33% of
Table 3 Participant characteristics
n = 278 Percent
Age 18–39 years old 27 10
40–59 years old 120 43
60+ 131 47
Gender Woman 244 88
Man 32 12
Gender fluid, non-binary, and/or Two-Spirit 1 < 1
Prefer not to say 1 < 1
Scleroderma type Limited 121 44
Diffuse 150 54
Other 7 3
Age at diagnosis 0–18 years old 8 3
18–39 years old 94 34
40–59 years old 141 51
60+ 35 13
Disease duration 0–4 years 37 13
5–9 years 77 28
10–19 years 99 36
20–29 years 38 14
30+ years 27 10




Côte d’Ivoire 1 < 1
Zambia 1 < 1
Identification* Aboriginal or indigenous 22 8
African American or Black 8 3
Asian 7 3
Caucasian 206 74
Hispanic or Latino(a) 10 4
South Asian 3 1
How I identify is not listed here 23 8
Prefer not to say 4 1
*Respondents could choose multiple categories
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the target sample size; this offers evidence of the exter-
nal validity of our predictions.
Figure 3 shows the potential impact of preferences for a
treatment on participation in an RCT of changing modifi-
able factors in the delivery of AHSCT to make the design
more “patient-oriented,” broadening the team involved in
care (by adding multidisciplinary care), offering treatment
closer to home (< 300 km), and reducing costs to individ-
uals ($0–$1000). Predicted participation, for a treatment
with the same risks and benefits, could be increased to
51% with all modifications. The potential contribution of
each modifiable factor is shown in in Fig. 4; offering a
treatment closer to home and at a lower cost appears to
most influence the likelihood of participation.
Discussion
This study revealed the preferences people with sclero-
derma have for potentially modifiable aspects of AHSCT,
how changes to these aspects could make the treatment
more acceptable, and in turn a trial of the treatment more
appealing to participate in. Understanding whether a
treatment is acceptable to the people it is intended for has
important implications in deciding whether or not a treat-
ment should be studied in a RCT and whether patients
will participate in a trial. Our results revealed that people
might be willing to trade key RCT outcomes (efficacy and
risks) for improvements in some modifiable procedural
factors (costs, distance of the treatment center to their
home, care team characteristics), highlighting that design-
ing treatments that align with patient preferences could
improve participation in RCTs. There are other factors in-
volved in choosing to participate in a trial, including the
chance of being randomized to a control arm, the uncer-
tain effects of the treatment [35, 36], but understanding
whether the proposed treatment is valuable for a patient is
a natural first step.
Our findings align with the literature that suggests that
other factors beyond clinical outcomes influence peo-
ple’s willingness to participate in RCTs [37]. Our study
expands on this knowledge by demonstrating how DCEs,
a quantitative preference-based method, can be used to
formally elicit and incorporate the preferences of pa-
tients into the design of RCTs. Such an approach has
the potential to maximize the value of using PPI in re-
search by involving patients from the early stages of the
study and designing surveys which can gather the per-
spectives of larger, representative groups of patients in a
relatively quick manner. If this type of pre-trial
Fig. 2 Preferences of people with scleroderma for aspects of stem-cell transplant treatment
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investigation is implemented, sub-group analysis could
be done to understand preferences of particularly hard-
to-recruit groups, such as minorities, and enhance suc-
cess of achieving more diverse participation in RCTs.
Moreover, incorporating patient preferences in early
stages of the RCT’s design might contribute to increase
the sustainability of clinical research by reducing avoidable
waste. There is concern about the extent of wasted invest-
ment in biomedical research and that promising research
findings too frequently do not enter routine clinical prac-
tice or translate to improvements in health care [4].
Among the key stages that lead to wasted research invest-
ment is a failure to address questions and interventions
that are most relevant to clinicians and patients and evalu-
ating these questions using outcomes that are not the
most important or relevant to patients [1]. Research waste
may thus be explained by patients not wanting the treat-
ment and services being researched.
DCEs are a well-established methodology in marketing
and health economics research. This study further shows
the potential value of the DCE methodology in the con-
text of RCT design. First, it indicates the potential to im-
prove recruitment rates by aligning modifiable process
characteristics of the treatment or intervention to be
studied in a trial with patient preferences. This potential
is supported by the close alignment of our predicted up-
take based on the preferences of people with sclero-
derma (34%), with the actual recruitment rate reported
in the SCOT trial, which was able to recruit only 33% of
their target sample size [18]. This is consistent with other
studies which support the external validity of DCEs [38].
Furthermore, the investigators of this trial listed potential
modifiable factors (transportation and insurance coverage
[18]) which align with key modifiable factors that affect
patient preferences in our study (cost and distance). Sec-
ondly, by replicating decision-making, which requires
trade-offs to be made between features of treatments,
these methods can reveal whether potential modifications
to treatments will influence participation in a RCT. For
example, we found that a holistic, multidisciplinary, team,
which was strongly endorsed as an important theme by
people with scleroderma in our qualitative work [22], did
not positively impact predicted participation in a trial. We
believe our results will be informative for the design of
any future trials of AHSCT for people with scleroderma,
as we have described the preferences and trade-offs for
Fig. 3 Predicted uptake of treatment based on preferences for autologous hematopoietic stem cell transplant for scleroderma processes
and outcomes
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the delivery of this treatment using a large, diverse sample
of people with scleroderma. However, our goal was also to
use this case study as an example of how choice-based
methods could be used to inform the design of future
RCTs. The power of choice-based methods are that they
help to isolate which factors are most important in influ-
encing decision-making (or most valued by individuals) by
presenting situations where multiple desirable aspects of a
treatment must be traded off against each other [39]. We
believe that this approach has applicability to both chronic
and acute conditions. While the options for varying pref-
erences in clinical practice may be more limited for acute
or time-limited conditions as compared to chronic condi-
tions, acute conditions are still preference-sensitive, i.e.,
requiring some form of trading between risks and benefits
as well as other aspects of care that contribute to overall
quality of care [40–42]. Because the opportunity to in-
corporate patient preferences for those other aspects of
quality care for acute conditions is limited at the point of
care, then one may argue that using preference methods
to inform the design of treatments for acute conditions
may be more pertinent than chronic conditions. Notwith-
standing this, we acknowledge that those modifiable as-
pects of treatment which extend beyond risks and benefits
but comprise quality care are likely different for patients
with acute and chronic diseases.
The interpretation of the results must consider that
the DCE developed in this study looked at preferences
for alternative hypothetical scenarios (stated prefer-
ences), and it is not known how these will match the ac-
tual choices (revealed preferences) if the alternatives
were to be available to patients. Nonetheless, our model
and predictions have shown favorable internal and exter-
nal validity. Furthermore, this study was both patient-
oriented, including people with scleroderma as patient
partners on the research team from the conception of
the study idea, to dissemination of results, and followed
best practice recommendations to identify all relevant
treatment attributes through qualitative research
methods. Finally, we acknowledge that while the SCOT
trial, which we use as the case study for this paper,
might not provide definitive information to inform
patient-physician decision-making, it does represent an
important step forward in treatment options for people
with severe scleroderma.
The feasibility of using methods like DCEs to under-
stand patient preferences in the design phase do warrant
consideration—there are concerns about the time and
funds required to conduct DCEs and that the results
may have limited predictive ability. Additionally, our
DCE predicts participation in a RCT based on prefer-
ences for a treatment, but not preferences to participate
Fig. 4 Predicted uptake of the treatment before and after modifications based on the preferences of people with scleroderma
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in a trial which offers a chance of being randomized to a
treatment. Considering these in order, using DCEs in
the design phase could add considerable time to the
process; however, it is worth noting that it is the time re-
quired to design a DCE (identifying key attributes and
their levels) and collect responses that is the time-
consuming component; the analysis and interpretation
of data is relatively quick. In case of proposed RCTs,
however, the non-modifiable attributes are likely to be
known and the potentially modifiable could be identified
as part of the PPI that is recommended as part of good
trial design [6–9]. Approaches like the nominal group
technique we used in this study could be formally con-
ducted as part the process of PPI and could quickly iden-
tify the priorities of patients for aspects of treatment. Our
study demonstrates that this NGT in itself can be valuable
as part of a patient-oriented approach, as well as directly
identifying key attributes for a DCE. The requirement for
funding to conduct a DCE as part of the design phase of
RCTs is also not a unique barrier; RCTs often require
funded feasibility and pilot studies to test trial design and
aspects of recruitment, and a DCE could be rolled into
data collection questionnaires and presented as part of
preliminary work required as components of an applica-
tion for funding the full RCT, just as sample size calcula-
tions are. Finally, the validity of predictions is a legitimate
concern—the disconnect between stated (hypothetical)
and revealed (actual) preferences (hypothetical bias) is well
documented [43], but a recent review and meta-analysis
found that stated preferences from DCEs can offer reason-
able predictions of subsequent health-related behaviors,
while cautioning a risk of over-predicting demand [44].
However, as long as any overprediction is consistent
across all estimates of participation in a trial, the results
should RCTs closer to the designs that reflect treatments
that patients want and would use. Furthermore, it is un-
likely that the incorporation of the preferences of larger,
more representative samples of potential trial participants
is likely to be detrimental in the design of RCTs. Finally,
we recognize that our DCE sought preferences which
allowed us to predict preferences for a treatment that
could be offered in an RCT and not preferences for a
treatment offered in the context of an RCT, i.e., subject to
randomization. The additional layer of uncertainty about
the treatment they would receive through randomization
is therefore not considered in our predictions. Other stud-
ies seeking to explore how preferences for treatment
alongside aspects of RCT design could inform people’s de-
cision about whether or not to participate, also using
DCEs [45]. However, while these studies complement our
approach, we believe that before deciding to design an
RCT, the first step is to determine whether the treatment
you would study is desirable and acceptable to people you
would recruit.
We propose that early studies, designed in collabor-
ation with patients and using methods such as DCEs,
should be a key part of designing RCTs to ensure that
scarce research resources are spent only on interventions
which address genuine patient needs, offer acceptable
and usable solutions, and deliver outcomes that are val-
ued by the people who matter—patients.
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